Mark G. Wise

American Veterinary Medical Association — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

29h-index2.9kcitations80works5.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Antibiotic Resistance in Bacteria(54), Antibiotic Use and Resistance(36), Antibiotics Pharmacokinetics and Efficacy(36), Bacterial Identification and Susceptibility Testing(11), Pneumonia and Respiratory Infections(7)

Publications80 total

P-1155. Activity of Ceftolozane/Tazobactam, Imipenem/Relebactam and Comparators Against non-Morganellaceae Enterobacterales and Pseudomonas aeruginosa Isolated from Patients with Invasive Respiratory Infections: SMART United States, 2021-2023
Open Forum Infectious Diseases·2026Open Access
112. Ceftolozane/Tazobactam Susceptibility Trends Among Gram-negative Bacilli Collected in the United States: SMART 2016 to 2023
Open Forum Infectious Diseases·2026Open Access
P-1156. In Vitro Antimicrobial Activity of Cefepime in Combination with Taniborbactam Against Resistant Clinical Gram-negative Isolates from a Global Collection, 2018-2023
Open Forum Infectious Diseases·2026Open Access
P-1157. In Vitro Antimicrobial Activity of Cefepime-Taniborbactam Against Molecularly Characterized Enterobacterales and P. aeruginosa Collected Worldwide from 2018-2023
Open Forum Infectious Diseases·2026Open Access
Trends in Pseudomonas aeruginosa In Vitro Susceptibility to Ceftolozane/Tazobactam in Latin America: SMART Surveillance Program, 2016–2024
Antibiotics·2025Open Access
P-1519. Susceptibility of Clinical Non-<i>Morganellaceae</i> Enterobacterales Isolates from Bloodstream and Respiratory Tract Infections to Imipenem/Relebactam and Comparators: SMART United States 2020-2022
Open Forum Infectious Diseases·2025Open Access
P-1521. Susceptibility of Carbapenem-Resistant Enterobacterales (CRE) and Carbapenem-Resistant <i>Pseudomonas aeruginosa</i> (CRPA) With and Without Carbapenemases to Cefepime-Taniborbactam and Comparators: GEARS Antimicrobial Surveillance Program, United States, 2018-2022
Open Forum Infectious Diseases·2025Open Access
P-1514. Cefepime-taniborbactam Exhibits Limited Cross-resistance with Ceftazidime-avibactam and Ceftolozane-tazobactam against Carbapenem-nonsusceptible Enterobacterales and Multidrug-resistant <i>Pseudomonas aeruginosa</i> from the United States 2018-2022
Open Forum Infectious Diseases·2025Open Access
P-1520. Addition of Relebactam Increases Susceptibility to Imipenem Among Imipenem-Intermediate <i>Pseudomonas aeruginosa</i>: Asia/Pacific SMART 2018-2022
Open Forum Infectious Diseases·2025Open Access
P-1355. Trends in Carbapenemase and Co-carbapenemase Production among Enterobacterales in Latin America: SMART 2018-2022
Open Forum Infectious Diseases·2025Open Access
P-1518. Activity of Ceftolozane/Tazobactam, Imipenem/Relebactam and Comparators Against Clinical MDR and DTR non-<i>Morganellaceae</i> Enterobacterales and <i>Pseudomonas aeruginosa</i> Stratified by Patient Age and Hospital Ward: SMART United States 2020-2022
Open Forum Infectious Diseases·2025Open Access
Antimicrobial Activity of Imipenem/Relebactam and Comparator Agents Against Gram-Negative Isolates Collected From Pediatric Patients: SMART 2018–2022 Global Surveillance
Journal of the Pediatric Infectious Diseases Society·2025· 1 cited
Susceptibility of Enterobacterales Collected in the Middle East and Turkey to Aztreonam/Avibactam and Comparator Agents Stratified by Infection Source: ATLAS Surveillance Program 2018-2022
Journal of Global Antimicrobial Resistance·2024Open Access
Cefepime–taniborbactam activity against antimicrobial-resistant clinical isolates of Enterobacterales and <i>Pseudomonas aeruginosa</i>: GEARS global surveillance programme 2018–22
Journal of Antimicrobial Chemotherapy·2024· 19 citedOpen Access
Susceptibility of Gram-negative pathogens collected in Israel to ceftolozane/tazobactam, imipenem/relebactam and comparators: SMART 2018–22
JAC-Antimicrobial Resistance·2024· 1 citedOpen Access
Global trends in carbapenem- and difficult-to-treat-resistance among World Health Organization priority bacterial pathogens: ATLAS surveillance program 2018–2022
Journal of Global Antimicrobial Resistance·2024· 68 citedOpen Access
<i>In vitro</i> activity of ceftazidime–avibactam and comparators against OXA-48-like Enterobacterales collected between 2016 and 2020
Microbiology Spectrum·2024· 2 citedOpen Access
Susceptibility of Gram-negative isolates collected in South Korea to imipenem/relebactam and comparator agents—SMART 2018–21
JAC-Antimicrobial Resistance·2023· 3 citedOpen Access
2149. <i>In vitro</i> Activity of Aztreonam-avibactam and Comparator Agents Against Carbapenem-Resistant Enterobacterales With and Without Carbapenemases, ATLAS Global Surveillance Program, 2017–2021
Open Forum Infectious Diseases·2023Open Access
2152. Activity of Imipenem/Relebactam Against Carbapenem-Resistant Non-<i>Morganellaceae</i> Enterobacterales (NME) in the United States – SMART 2019-2021
Open Forum Infectious Diseases·2023Open Access
page 1 of 4Next →

Frequent Co-authors

Daniel F. Sahm(25), Meredith Hackel(12), Bruce S. Seal(7), Gregory R. Siragusa(7), Krystyna M. Kazmierczak(7), James A. Karlowsky(7), J. Vaun McArthur(6), Lawrence J. Shimkets(6), Katherine Young(6), Gregory G. Stone(5), Fakhar Siddiqui(5), Mary Motyl(5), Yoshinori Yamano(4), James A. Karlowsky(4), Dennis A. Senne(3), Daniel J. King(3), Darrell R. Kapczynski(3), Roger Echols(3), Rene Alvarez(3), Daniel C. Pevear(3)